Stock THERAVANCE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Theravance Inc Nasdaq

Equities

US88338T1043

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Theravance Inc
06-18 Cantor Fitzgerald Initiates Innoviva at Overweight Rating MT
06-10 Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cantor Fitzgerald Initiates Innoviva at Overweight Rating
MT
Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
PU
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
MT
Transcript : Innoviva, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
Innoviva: Q1 Earnings Snapshot
AQ
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M
MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
CI
Innoviva, Inc. Appoints Derek Small to the Board of Directors
CI
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BU
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Innoviva to Participate in the BofA Securities Health Care Conference
BU
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
AQ
Innoviva, Inc.'s Equity Buyback announced on November 9, 2022, has closed with 7,807,887 shares, representing 11.78% for $100 million.
CI
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
BU
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
MT
North American Morning Briefing : Stock Futures -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVA Stock
  4. Stock
  5. News Theravance Inc